Yan Shi

ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models

Cherrie K. Donawho, Yan Luo, Yanping Luo et al. · Clinical Cancer Research · 2007 · 773 citations · Full text

Medicine, Oncology, Pharmacology +15

Discovery of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor 2-[(<i>R</i>)-2-methylpyrrolidin-2-yl]-1<i>H</i>-benzimidazole-4-carboxamide (ABT-888) for the Treatment of Cancer

Thomas D. Penning, Gui‐Dong Zhu, Viraj B. Gandhi et al. · Journal of Medicinal Chemistry · 2008 · 269 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

Mechanistic Dissection of PARP1 Trapping and the Impact on <i>In Vivo</i> Tolerability and Efficacy of PARP Inhibitors

Todd A. Hopkins, Yan Shi, Luis E. Rodrı́guez et al. · Molecular Cancer Research · 2015 · 267 citations

Medicine, Oncology, Pharmacology +17

Potent and selective inhibitors of Akt kinases slow the progress of tumors <i>in vivo</i>

Yan Luo, Alexander R. Shoemaker, Xuesong Liu et al. · Molecular Cancer Therapeutics · 2005 · 244 citations · Full text

Medicine, Oncology, Pharmacology +15

Iniparib Nonselectively Modifies Cysteine-Containing Proteins in Tumor Cells and Is Not a <i>Bona Fide</i> PARP Inhibitor

Xuesong Liu, Yan Shi, David Maag et al. · Clinical Cancer Research · 2011 · 175 citations · Full text

Medicine, Oncology, Pharmacology +11